


UHPLC Analysis of Reduced IgG1 on BIOshell™ IgG 1000 Å Diphenyl



Peak Number	Compound	Concentration µg/mL
1	Trastuzumab Light Chain	400
2	Trastuzumab Heavy Chain	400

Conditions:

column:	BIOshell™ IgG 1000 Å Diphenyl, 15 cm x 2.1 mm I.D., 2.7 µm
mobile phase:	[A] Water (0.1% v/v TFA); [B] Acetonitrile (0.1% v/v TFA)
gradient:	30% B to 40% B in 14.0 min
flow rate:	0.4 mL/min
column temp.:	80 °C
detector:	UV 280 nm, PDA
injection:	2 µL
sample:	reduced Trastuzumab, 400 µg/mL, water with 1.2M Guanidine/0.1% TFA

Description:

The 2.7 µm BIOshell™ IgG Diphenyl is ideal for analysis of monoclonal antibodies such as trastuzumab. Trastuzumab is a monoclonal antibody that is used primarily to treat breast cancer, but can also be used in the treatment of stomach and esophageal cancers. 2 mg/mL trastuzumab was incubated at 60 °C for 1 hour using 20 mM DTT, 6 M Guanidine, and 50 mM Tris pH 7.8. This separation of the light and heavy chains is useful for quantification and analysis.

Materials:

Product Part Number	Description
270733	Water
34851	Acetonitrile
302031	TFA
577421-U	BIOshell™ IgG 1000 Å Diphenyl 2.7 µm 15 cm x 2.1 mm